Recombinant HDL Milano exerts greater anti-inflammatory and plaque stabilizing properties than HDL wild-type

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 72-77

  Ibanez, Borja ^a,b,c   Giannarelli, Chiara ^a   Cimmino, Giovanni ^a   Santos Gallego, Carlos G ^a   Alique, Matilde ^a   Pinero, Antonio ^a   Vilahur, Gemma ^a,d   Fuster, Valentin ^a,b   Badimon, Lina ^d   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

ApoA I; Apolipoproteins; Atherosclerosis; HDL; Magnetic resonance imaging; Plaque; Plaque vulnerability

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CASPASE 3; CHOLESTEROL; CYCLOOXYGENASE 2; ETC 216; GELATINASE A; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; SCAVENGER RECEPTOR BI;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DENSITY; CONTROLLED STUDY; DRUG INFUSION; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; IN VITRO STUDY; INFLAMMATION; LIVER; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD36; ANTIOXIDANTS; AORTA, ABDOMINAL; AORTIC DISEASES; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CASPASE 3; CELL LINE; CHEMOKINE CCL2; CHOLESTEROL; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; INFUSIONS, INTRAVENOUS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVER; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MATRIX METALLOPROTEINASE 2; OXIDATIVE STRESS; PHOSPHATIDYLCHOLINES; RABBITS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 84155166795     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.006     Document Type: Article

References (31)

1. Giannarelli C., Zafar M.U., Badimon J.J. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism?. Thromb Haemost 2011, 104:949-954.
2. Ibanez B., Vilahur G., Badimon J.J. Plaque progression and regression in atherothrombosis. J Thromb Haemost 2007, 5(Suppl. 1):292-299.
3. Hansson G.K., Inflammation atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
4. Steffel J., Luscher T.F., Tanner F.C. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006, 113:722-731.
5. Santos-Gallego C.G., Ibanez B., Badimon J.J. HDL-cholesterol: is it really good? Differences between apoa-i and hdl. Biochem Pharmacol 2008, 76:443-452.
6. Shah P.K. Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach. Curr Pharm Des 2007, 13:1031-1038.
7. Chyu K.Y., Peter A., Shah P.K. Progress in HDL-based therapies for atherosclerosis. Curr Atheroscler Rep 2011.
8. Tall A.R., Yvan-Charvet L., Terasaka N., Pagler T., Wang N. Hdl abc transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 2008, 7:365-375.
9. Choi B.G., Vilahur G., Yadegar D., Viles-Gonzalez J.F., Badimon J.J. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 2006, 6:571-587.
10. Yin K., Deng X., Mo Z.C., et al. Tristetraprolin-dependent post-transcriptional regulation of inflammatory cytokine mRNA expression by apolipoprotein A-I: role of ATP-binding membrane cassette transporter a1 and signal transducer and activator of transcription 3. J Biol Chem 2011, 286:13834-13845.
11. Kaul S., Shah P.K. ApoA-I milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:471-479.
12. Forrester J.S., Shah P.K. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol 2006, 98:1542-1549.
13. Franceschini G., Sirtori C.R., Capurso A., Weisgraber K.H., Mahley R.W. A-Imilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980, 66:892-900.
14. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
15. Ibanez B., Vilahur G., Cimmino G., et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 2008, 51:1104-1109.
16. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990, 85:1234-1241.
17. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.
18. Waksman R., Torguson R., Kent K.M., et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010, 55:2727-2735.
19. Corti R., Osende J., Hutter R., et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis 2007, 190:106-113.
20. Speidl W.S., Cimmino G., Ibanez B., et al. Recombinant apolipoprotein A-I milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J 2010, 31:2049-2057.
21. Zannis V.I., Chroni A., Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006, 84:276-294.
22. Gaubatz J.W., Ballantyne C.M., Wasserman B.A., et al. Association of circulating matrix metalloproteinases with carotid artery characteristics: the atherosclerosis risk in communities carotid MRI study. Arterioscler Thromb Vasc Biol 2011, 30:1034-1042.
23. Volcik K.A., Campbell S., Chambless L.E., et al. MMP2 genetic variation is associated with measures of fibrous cap thickness: the atherosclerosis risk in communities carotid MRI study. Atherosclerosis 2010, 210:188-193.
24. Weibel G.L., Alexander E.T., Joshi M.R., et al. Wild-type apoA-I and the milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol 2007, 27:2022-2029.
25. Franceschini G., Calabresi L., Chiesa G., et al. Increased cholesterol efflux potential of sera from apoA-Imilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999, 19:1257-1262.
26. Favari E., Gomaraschi M., Zanotti I., et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(milano) dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux. J Biol Chem 2007, 282:5125-5132.
27. Lebherz C., Sanmiguel J., Wilson J.M., Rader D.J. Gene transfer of wild-type ApoA-I and ApoA-I milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol 2007, 6:15.
28. Parolini C., Chiesa G., Gong E., et al. Apolipoprotein A-I and the molecular variant ApoA-I(milano): evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis 2005, 183:222-229.
29. Feng Y., Van Craeyveld E., Jacobs F., Lievens J., Snoeys J., De Geest B. Wild-type apo A-I and apo A-I(milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. J Mol Med 2009, 87:287-297.
30. Moore R.E., Navab M., Millar J.S., et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 2005, 97:763-771.
31. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999, 40:345-353.